While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

When the FDA unexpectedly uploaded around 200 drug rejection letters this week, the regulator provided a rare glimpse in | ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

According to a pair of recent rulings by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA), Jazz ...

Eight drugmakers agreed to put legal claims stemming from their roles in the U.S. | Viatris, Hikma, Amneal, Apotex, Indivior, ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Nearly 70 years into her history, Barbie is still undergoing regular makeovers. | Nearly 70 years into her history, Barbie is ...

After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the ...

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...

Renee Gala joins a short list of female biopharma chief executives as she is set to take the reins at Jazz Pharmaceuticals, ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...